DeborahLToppmeyerMD

PubMed

• Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.
  Jinghua An, Jean McDougall, Yong Lin, Shou-En Lu, Scott T Walters, Emily Heidt, Antoinette Stroup, Lisa Paddock, Sherry Grumet, Deborah Toppmeyer, Anita Y Kinney> ;JNCI Cancer Spectrum. 2024 Feb 29
• Ovarian Suppression: Early Menopause, Late Effects.
  Goldberg, C., Greenberg, M., Noveihed, A., Agrawal, L., Omene, C., Toppmeyer, D., George, M.> ;Current Oncology Reports. 2024 Jan 2
• Long-Term Clinical and Cosmetic Outcomes of Once-Daily Accelerated Partial Breast Irradiation in Early Breast Cancer.
  Kumar, R., Krupa, K., Yehia, Z., Kumar, S., Potdevin, L., Eladoumikdachi, F., Kowzun, M., Goyal, S., Ohri, N., Toppmeyer, D., Haffty, B.> ;Advances in Radiation Oncology. 2024 Jan 1
• Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study.
  Sarah J Fadem, Benjamin F Crabtree, Denalee M O'Malley, Lisa Mikesell, Jeanne M Ferrante, Deborah L Toppmeyer, Pamela A Ohman-Strickland, Jennifer R Hemler, Jenna Howa...> ;BMC Primary Care. 2023 Nov 9
• Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.
  Jinghua An, Shou-En Lu, Jean McDougall, Scott T Walters, Yong Lin, Emily Heidt, Antoinette Stroup, Lisa Paddock, Sherry Grumet, Deborah Toppmeyer, Anita Y Kinney> ;Annals of Behavioral Medicine. 2023 Oct 16
• 3 citations
  Clinical efficacy of PARP inhibitors in breast cancer.
  Karan Pandya, Alyssa Scher, Coral Omene, Shridar Ganesan, Shicha Kumar, Nisha Ohri, Lindsay Potdevin, Bruce Haffty, Deborah L Toppmeyer, Mridula A George> ;Breast Cancer Research and Treatment. 2023 Jul 1
• 9 citations
  Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory An...
  Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji ...> ;JCO Precision Oncology. 2023 Apr 1
• Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
  Geena Chacko, Srigowri Kota, Shicha Kumar, Nisha Ohri, Coral Omene, Shridar Ganesan, Deborah L Toppmeyer, Mridula A George> ;Anti-Cancer Drugs. 2023 Apr 1
• 1 citations
  Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
  Anita Y Kinney, Scott T Walters, Yong Lin, Shou-En Lu, Arreum Kim, Julianne Ani, Emily Heidt, Circe J G Le Compte, Denalee O'Malley, Antoinette Stroup, Lisa E Paddock,...> ;Journal of Clinical Oncology. 2023 May 20
• HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment.
  Gandarillas, S., Newland, E., Denzin, L., Toppmeyer, D., Stephenson, R., Dasgeb, B.> ;Frontiers in Medicine. 2023 Jan 1
• 10 citations
  Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker.
  Sadaf Qureshi, Nancy Chan, Mridula George, Shridar Ganesan, Deborah Toppmeyer, Coral Omene> ;Biomarker Insights. 2022 Jan 1
• Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.
  Circe Gray Le Compte, Shou-En Lu, Julianne Ani, Jean McDougall, Scott T Walters, Deborah Toppmeyer, Tawny W Boyce, Antoinette Stroup, Lisa Paddock, Sherry Grumet, Yong...> ;Health Psychology and Behavioral Medicine. 2022 Jan 1
• 55 citations
  Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
  Mridula George, Sadaf Qureshi, Coral Omene, Deborah Toppmeyer, Shridar Ganesan> ;Frontiers in Oncology. 2021 Jul 12
• 8 citations
  Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
  Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral S. Grandhi, Shridar Ganesan, Deborah Toppmeyer, Lin...> ;Case Reports in Oncology. 2021 Jun 18
• 20 citations
  Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy
  Mark Jesus M. Magbanua, Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford A. Hudis, Deborah Toppmeyer, Lisa A. Carey, Ann H. Partridge, Jean-Yv...> ;Journal of the National Cancer Institute. 2021 Apr 6
• 3 citations
  SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center.
  Mansi Shah, Imraan Jan, Jeremy Johns, Kuldip Singh, Pallavi Kumar, Norma Belarmino, Kara J. Saggiomo, Carolyn Hayes, Kimyatta Washington, Deborah Toppmeyer, Bruce G. H...> ;Cancer. 2021 Feb 18
• 2 citations
  Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy
  Mutlay Sayan, Irina Vergalasova, Sachin R. Jhawar, Shicha Kumar, Mridula George, Maria Kowzun, Lindsay Potdevin, Deborah Toppmeyer, Bruce G. Haffty, Nisha Ohri> ;Clinical Breast Cancer. 2021 Feb 1
• 58 citations
  Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
  Kathy S. Albain, Robert Gray, Della F. Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, S...> ;Journal of the National Cancer Institute. 2021 Apr 6
• 6 citations
  Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
  Deborah Toppmeyer, Michael F. Press> ;Cancer Medicine. 2020 Jul 22
• 17 citations
  5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.
  Matthew M. Poppe, Zeinab Abou Yehia, Christopher Baker, Sharad Goyal, Deborah Toppmeyer, Laurie J Kirstein, Chunxia Chen, Dirk F. Moore, Bruce G. Haffty, Atif J. Khan> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Jul 15
• 4 citations
  Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
  Manish R. Sharma, Shailly Mehrotra, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford A. Hudis, Eric P. Winer, Alan P. Lyss, Deborah Toppmeyer, Alvaro Moreno-Aspiti...> ;Journal of Clinical Pharmacology. 2020 Apr 1
• 483 citations
  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
  Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Cur...> ;Annals of Oncology. 2019 Mar 1
• 94 citations
  Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analys...
  Joseph A. Sparano, Robert Gray, DF Makower, Kathy S. Albain, Thomas James Saphner, Sunil Badve, Lynne I. Wagner, Virginia G. Kaklamani, Maccon M. Keane, Henry L. Gomez...> ;JAMA Oncology. 2020 Mar 1
• 74 citations
  TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFOR...
  Nadine Tung, Banu Arun, Michele R. Hacker, E Hofstatter, Deborah Toppmeyer, Steven J. Isakoff, Virginia F. Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff,...> ;Journal of Clinical Oncology. 2020 Feb 25
• 43 citations
  Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
  Rachid Karam, Blair R. Conner, Holly LaDuca, Kelly McGoldrick, Kate Krempely, Marcy E. Richardson, Heather Zimmermann, Stephanie Gutierrez, Patrick Reineke, Lily Hoang...> ;JAMA Network Open. 2019 Oct 2
• Join now to see all